Compass Therapeutics, Inc.
Compass Therapeutics, Inc. (Nasdaq: CMPX) is a clinical-stage biopharmaceutical company developing antibody-based therapeutics, primarily for cancer. Its research focuses on angiogenesis, the immune system and tumor growth, with candidates designed to affect tumor blood vessels and immune responses. The company has… From the company’s description.
In fiscal 2025, Compass Therapeutics, Inc. reported a net loss of $66.49M. Operations used $49.14M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Compass Therapeutics, Inc. does
In the company’s own words
Compass Therapeutics, Inc. (Nasdaq: CMPX) is a clinical-stage biopharmaceutical company developing antibody-based therapeutics, primarily for cancer. Its research focuses on angiogenesis, the immune system and tumor growth, with candidates designed to affect tumor blood vessels and immune responses. The company has four clinical-stage candidates: tovecimig, a DLL4/VEGF-A bispecific antibody being studied in solid tumors; CTX-471, an antibody that activates the CD137 immune receptor; CTX-8371, a bispecific antibody targeting PD-1 and PD-L1; and CTX-10726, a bispecific antibody targeting PD-1 and VEGF-A. The candidates are intended for development as standalone therapies and in combinations with other drugs or pipeline antibodies. Compass also develops additional antibody candidates through its research and discovery platform. It holds exclusive global rights outside South Korea to tovecimig, originally licensed from South Korea-based ABL Bio, and its wholly owned subsidiaries include Trigr Therapeutics. Compass Therapeutics reports a pipeline rather than operating revenue segments; it has no products approved for commercial sale. Its website is https://compasstherapeutics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1738021
- SIC
- 2836
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Compass Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Compass Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Compass Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Compass Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Compass Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”